<a href="https://www.fiercebiotech.com/biotech/apogee-bags-13b-royalty-funding-deal-push-eczema-challenger-phase-3" hreflang="en">Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3</a>
Apogee Therapeutics has secured up to $1.3 billion in royalty funding from Blackstone Life Sciences to advance its eczema treatment, zumilokibart, into phase 3 trials. The deal includes immediate and milestone-based payments, marking it as the largest royalty financing for a pre-phase 3 program to date, while also positioning Apogee for potential commercialization and profitability.
Apogee Therapeutics' ability to secure a $1.3 billion royalty funding deal from Blackstone Life Sciences for their phase 3 eczema drug highlights a significant trend in biotech financing: large-scale, non-dilutive funding as a strategic pathway to advance late-stage drug development and commercialization. This approach not only mitigates equity dilution but also positions Apogee to aggressively pursue further pipeline development, suggesting a strategic model for other biotech firms seeking to balance funding needs with maintaining equity control.